- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 3/06 - Antihyperlipidemics
Patent holdings for IPC class A61P 3/06
Total number of patents in this class: 4658
10-year publication summary
|
186
|
185
|
178
|
247
|
300
|
305
|
339
|
339
|
292
|
81
|
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Kowa Company, Ltd. | 1172 |
73 |
| Takeda Pharmaceutical Company Limited | 2961 |
59 |
| Shionogi & Co., Ltd. | 914 |
54 |
| Daiichi Sankyo Company, Limited | 1829 |
50 |
| Janssen Pharmaceutica N.V. | 3839 |
45 |
| Amarin Pharmaceuticals Ireland Limited | 267 |
44 |
| Amgen Inc. | 3779 |
42 |
| Regeneron Pharmaceuticals, Inc. | 3650 |
37 |
| Mochida Pharmaceutical Co., Ltd. | 334 |
35 |
| AstraZeneca AB | 3042 |
34 |
| Novartis AG | 11238 |
31 |
| F. Hoffmann-La Roche AG | 7958 |
30 |
| Boehringer Ingelheim International GmbH | 4629 |
28 |
| Bristol-myers Squibb Company | 5080 |
27 |
| Banyu Pharmaceutical Co., Ltd. | 107 |
27 |
| Eli Lilly and Company | 3645 |
25 |
| Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 762 |
25 |
| Japan Tobacco Inc. | 3225 |
24 |
| Taisho Pharmaceutical Co., Ltd. | 844 |
24 |
| Alnylam Pharmaceuticals, Inc. | 1066 |
21 |
| Other owners | 3923 |